Target intelligence / Profile preview

Enterotoxigenic Escherichia coli B7A surface antigen

Molecular classification
Other (surface antigen), Bacterial adhesin, Outer membrane protein, Fimbrial/colonization factor protein, Autotransporter protein
01

Overview

Enterotoxigenic Escherichia coli (ETEC) B7A surface antigens comprise a heterogeneous collection of proteins and glycoproteins located on the bacterial outer membrane, including colonization factor antigens (such as CS6), autotransporters (such as antigen 43 and EatA), fimbrial subunits, and other virulence-associated proteins. These molecules mediate ETEC’s initial adhesion to intestinal epithelial cells, facilitate colonization and persistence, and modulate host immune responses. In ETEC B7A specifically, CS6 is the principal colonization factor, and sequence analyses indicate the presence of additional surface-exposed proteins such as Ag43, pAT, and dispersin-like proteins (CexE), but strain B7A does not carry all antigens found in some other ETEC strains, notably lacking the EtpA adhesin[2][4][5][6]. Immune responses to these antigens are detectable in infected hosts, and several are under consideration as vaccine targets due to their role in virulence and ability to elicit protective immunity. However, antigenic variation poses a challenge for broad-coverage vaccine design[2][7][4][5]. Note: For structured target data or experimental work, it is recommended to refer to individual well-characterized antigens such as "CS6 fimbrial subunit CssA" or "antigen 43" rather than the general category "ETEC B7A surface antigens"[2][4].

Other names
ETEC B7A surface proteinsSurface-exposed antigens of ETEC B7AETEC B7A outer membrane antigens
02

Mechanism of action

As vaccine antigens: induce production of neutralizing antibodies blocking bacterial adhesion or neutralizing virulence factors[2][7].

03

Biological functions

Adhesion to host intestinal epithelial cellsEvasion of host immune responseColonizationDelivery of toxic proteins (enterotoxins)
04

Disease associations

Infection (cause of diarrheal illness via pathogenesis of ETEC)Virulence
05

Safety considerations

Antigenic diversity among ETEC strains limits cross-protective efficacy of vaccines targeting single antigens[2][7].Potential for antigenic heterogeneity to permit immune escape.
06

Interacting drugs

No approved drugs directly target ETEC B7A surface antigens; experimental or vaccine approaches target these proteins[7][2].
07

Biomarkers

Antibodies against ETEC colonization factors (e.g., CS6, Ag43, EatA) in convalescent sera are used in research as response/diagnostic biomarkers for exposure/infection[2][3][4].

Beyond the preview

Go deeper on Enterotoxigenic Escherichia coli B7A surface antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterotoxigenic Escherichia coli B7A surface antigen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call